Federal Jury Convicts Reedley Biolab Operator in Multi-Million Dollar COVID-19 Test Fraud

A federal jury has delivered a guilty verdict against Jia Bei Zhu, the operator of a biolab in Reedley, California, following a scheme to profit from the global pandemic. Zhu was found guilty of orchestrating a fraudulent operation that sold millions of faulty and misbranded COVID-19 tests to customers across the United States.

The case highlights a significant breach of public trust and regulatory oversight, as the defendant not only distributed unreliable medical diagnostics but also actively deceived federal authorities to maintain the operation.

The Mechanics of the Fraud: Universal Meditech Inc.

Operating through his Fresno-based company, Universal Meditech Inc. (UMI), Jia Bei Zhu, a 64-year-old Chinese national, managed a sophisticated scheme to sell substandard medical supplies. According to court records and the Department of Justice, Zhu fraudulently sold more than a million COVID-19 tests.

The financial scale of the fraud was substantial. While some reports cite the scheme at $3.8 million, the U.S. Attorney’s Office notes that the tests were sold for nearly $4 million. These tests were marketed as reliable diagnostic tools, yet they were found to be faulty and misbranded, potentially providing inaccurate results to thousands of users during a critical period of the public health crisis.

Deceiving the FDA

Beyond the sale of faulty products, the jury found that Zhu engaged in a deliberate effort to mislead the U.S. Food and Drug Administration (FDA). The conviction includes findings that Zhu lied to the agency regarding his true identity and his specific role within Universal Meditech Inc.

From a clinical perspective, this level of deception is particularly egregious. The FDA’s regulatory framework exists to ensure that medical devices and diagnostics meet strict safety and efficacy standards. By falsifying his identity and role, Zhu bypassed essential oversight, allowing misbranded tests to enter the American healthcare stream without proper verification.

Why “Misbranded” and “Faulty” Tests Matter

In medicine, a diagnostic test is only as good as its sensitivity, and specificity. When a test is “faulty” or “misbranded,” it means it does not perform as advertised. For a COVID-19 test, this can lead to two dangerous outcomes:

• False Negatives: An infected person is told they are healthy, leading them to unknowingly spread the virus to vulnerable populations.
• False Positives: A healthy person is told they are infected, leading to unnecessary quarantine, psychological stress, and wasted medical resources.

The distribution of these tests wasn’t just a financial crime; it was a gamble with public health. When the tools we use to manage an infectious disease are compromised, the entire strategy for containment and treatment fails.

Frequently Asked Questions

What was the role of Universal Meditech Inc. (UMI)?

UMI was the Fresno-based company used by Jia Bei Zhu to sell more than a million fraudulent COVID-19 tests across the United States.

Why was the FDA involved in this case?

The FDA is responsible for regulating medical tests. Zhu was convicted of lying to the FDA about his identity and his role at UMI to evade proper regulatory scrutiny.

What is the total amount of money involved in the scheme?

The scheme involved the sale of tests for nearly $4 million, with some reports specifying the amount as $3.8 million.

Looking Ahead

The conviction of Jia Bei Zhu serves as a stern warning to operators of medical laboratories and suppliers. As the healthcare industry continues to recover from the pandemic, federal agencies are likely to increase scrutiny on the supply chain for diagnostic tools to prevent similar fraudulent schemes. For patients and providers, this case underscores the importance of sourcing medical diagnostics from verified, FDA-cleared manufacturers.